Cascadian Therapeutics Inc. buy melinda
Start price
15.10.17
/
50%
€3.92
Target price
01.11.17
€4.51
Performance (%)
3.45%
End price
01.11.17
€4.06
Summary
This prediction ended on 01.11.17 with a price of €4.06. With a performance of 3.45%, the BUY prediction by melinda for Cascadian Therapeutics Inc. closed with a slight gain. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Cascadian Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | -0.598% | 0.645% | 10.813% | 15.396% |
| iShares Nasdaq 100 | -3.290% | -4.193% | 23.772% | 40.773% |
| iShares Nikkei 225® | -0.796% | -0.582% | 8.390% | 8.288% |
| iShares S&P 500 | -1.164% | -0.857% | 23.003% | 41.152% |
Comments by melinda for this prediction
In the thread Cascadian Therapeutics Inc. diskutieren
Versuch Inhibitor
Cascadian Therapeutics, Inc. (NASDAQ: CASC), ein biopharmazeutisches Unternehmen , in klinischen Studien, hat heute bekannt gegeben , dass die Food and Drug Administration ( "FDA") in den Vereinigten Staaten als Orphan Drug erteilt hat für die Behandlung tucatinib HER2-positive metastasierendem Kolorektalkarzinom (HER2 +). Die tucatinib ist ein Prüfpräparat oral zu verabreichender Hemmer hochselektiver Kinase kleinen Moleküls ...
Stopped prediction by melinda for Cascadian Therapeutics Inc.
Cascadian Therapeutics Inc.
Start price
Target price
Perf. (%)
€4.35
15.10.17
15.10.17
€5.00
01.11.17
01.11.17
3.45%
01.11.17
01.11.17
Cascadian Therapeutics Inc.
Start price
Target price
Perf. (%)
€3.28
23.01.17
23.01.17
€4.51
06.03.17
06.03.17
14.24%
06.03.17
06.03.17
Cascadian Therapeutics Inc.
Start price
Target price
Perf. (%)
€6.61
07.06.16
07.06.16
€7.58
21.09.16
21.09.16
15.38%
21.09.16
21.09.16
Cascadian Therapeutics Inc.
Start price
Target price
Perf. (%)
€9.12
17.05.13
17.05.13
€12.00
18.11.13
18.11.13
-6.18%
18.11.13
18.11.13
Cascadian Therapeutics Inc.
Start price
Target price
Perf. (%)
€15.16
01.10.10
01.10.10
€18.00
01.04.11
01.04.11
6.13%
01.04.11
01.04.11